Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease

NCT03326063 is registered in ClinicalTrials.gov with Brigham and Women's Hospital as lead sponsor.

NCT NCT03326063
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03326063 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Therapeutic Control of Aspirin-Exacerbated Respiratory Disease
Lead sponsor
Brigham and Women's Hospital
Phase
Phase 2
Overall status
Completed
Start date
April 26, 2018
Completion date
April 15, 2023
Enrollment
38 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

aspirin-exacerbated respiratory disease, aspirin-sensitive asthma with nasal polyps, asthma, aspirin-induced, nasal polyps